OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
INTERPHEX 2025: ‘Breaking Up the Octopus’ of Single-Use Systems
As single use becomes more prevalent, end users are looking for more customization, and regulators are refining their rules, says Todd Andrews of CPC in an interview with Pharmaceutical Technology® Group.
When single-use technologies began to be adopted, the attitude in the bio/pharmaceutical industry was a “wild wild West,” says Todd Andrews, global director of Applications and Business Development for CPC’s Biopharma business. Andrews spoke exclusively with Pharmaceutical Technology® Group at INTERPHEX 2025 in New York City.
Andrews is also secretary of the executive board of directors of the Bio-Process Systems Alliance, and in that capacity, he said one current priority is keeping abreast of new and changing regulations regarding single-use technologies, which are evolving in a similar fashion to those concerning per- and polyfluoroalkyl substances, or PFAS.
Being able to customize services and offerings for individual customers is another important touchstone, according to Andrews.
“What we're seeing now is a lot of forward-thinking end users trying to break up—we call it ‘break up the octopus’,” Andrews says in the interview. “Instead of this giant tubing assembly, how do you break it up into the common subassemblies? And you almost can treat it like a Lego, where you may have a ‘T’ or a cross and you can basically customize at the point of use, instead of customizing with the OEM [original equipment manufacturer]. And if you're an OEM supplying this, this adds a lot more efficiency, because now, instead of making lower volumes of multiple part numbers, you can make higher volumes of lower part numbers.”
The 2025 edition of INTERPHEX took place from April 1–3, 2025 in New York City.
Click the video above to watch the full interview.
Click here for more conference coverage.
About the speaker
Todd Andrews, Global Director, Applications and Business Development, CPC
Todd Andrews is global director—Applications and Business Development for CPC's Biopharma business. For more than 20 years, he has focused on single-use connection technology development and integration into the bioprocessing industry, in addition to the emerging cell and gene therapy markets. With a Bachelor of Science degree in plastics engineering and a Master of Business Administration, Andrews has held roles in design engineering, product management, business development, and sales. Andrews also currently serves as secretary on the Bio-Process Systems Alliance (BPSA) executive board of directors.
